Literature DB >> 16081029

Apoptotic modifications affect the autoreactivity of the U1 snRNP autoantigen.

D Hof1, Jos M H Raats, Ger J M Pruijn.   

Abstract

A hallmark of systemic autoimmune diseases is the presence of high titers of serum autoantibodies targeting a diversity of autoantigens. Most components of the U1 snRNP complex are autoantigenic in systemic lupus erythematosus (SLE) and SLE overlap syndrome, which is also called mixed connective tissue disease (MCTD). It is hypothesized that posttranslational modifications, in particular cell death-associated modifications, play an important role in breaking tolerance to self-antigens. Recently, it became clear that the U1 snRNP particle, more specifically its U1-70K protein component, displays a new epitope during apoptosis. This review intends to give an overview of the modifications that occur on the U1 snRNP autoantigens, especially those arising during cell death, to summarize recent data describing autoantibody reactivities with apoptosis-specific epitopes on the U1 snRNP complex, and to provide some insight into the mechanisms that might underlie the immune response to self-antigens.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16081029     DOI: 10.1016/j.autrev.2005.02.003

Source DB:  PubMed          Journal:  Autoimmun Rev        ISSN: 1568-9972            Impact factor:   9.754


  10 in total

Review 1.  Apoptotic cell death and lupus.

Authors:  Philip L Cohen
Journal:  Springer Semin Immunopathol       Date:  2006-08-29

2.  Epitope mapping of the U1 small nuclear ribonucleoprotein particle in patients with systemic lupus erythematosus and mixed connective tissue disease.

Authors:  J A Somarelli; A Mesa; R Rodriguez; R Avellan; L Martinez; Y J Zang; E L Greidinger; R J Herrera
Journal:  Lupus       Date:  2011-03       Impact factor: 2.911

Review 3.  A novel pathogenetic concept-antiviral immunity in lupus nephritis.

Authors:  Adriana Migliorini; Hans-Joachim Anders
Journal:  Nat Rev Nephrol       Date:  2012-01-17       Impact factor: 28.314

4.  A Streamlined Data Analysis Pipeline for the Identification of Sites of Citrullination.

Authors:  Aaron J Maurais; Ari J Salinger; Micaela Tobin; Scott A Shaffer; Eranthie Weerapana; Paul R Thompson
Journal:  Biochemistry       Date:  2021-09-07       Impact factor: 3.321

Review 5.  The pathogenesis of lupus nephritis.

Authors:  Maciej Lech; Hans-Joachim Anders
Journal:  J Am Soc Nephrol       Date:  2013-08-08       Impact factor: 10.121

Review 6.  U1-RNP and TLR receptors in the pathogenesis of mixed connective tissue diseasePart I. The U1-RNP complex and its biological significance in the pathogenesis of mixed connective tissue disease.

Authors:  Agnieszka Paradowska-Gorycka
Journal:  Reumatologia       Date:  2015-05-18

7.  Interferons (IFN-A/-B/-G) Genetic Variants in Patients with Mixed Connective Tissue Disease (MCTD).

Authors:  Agnieszka Paradowska-Gorycka; Anna Wajda; Barbara Stypinska; Ewa Walczuk; Marcela Walczyk; Anna Felis-Giemza; Aleksandra Poluch; Marzena Olesińska
Journal:  J Clin Med       Date:  2019-11-21       Impact factor: 4.241

8.  Activation of interferon regulatory factor-3 via toll-like receptor 3 and immunomodulatory functions detected in A549 lung epithelial cells exposed to misplaced U1-snRNA.

Authors:  Christian D Sadik; Malte Bachmann; Josef Pfeilschifter; Heiko Mühl
Journal:  Nucleic Acids Res       Date:  2009-06-18       Impact factor: 16.971

9.  Isoforms of U1-70k control subunit dynamics in the human spliceosomal U1 snRNP.

Authors:  Helena Hernández; Olga V Makarova; Evgeny M Makarov; Nina Morgner; Yutaka Muto; Daniel Pomeranz Krummel; Carol V Robinson
Journal:  PLoS One       Date:  2009-09-28       Impact factor: 3.240

10.  Effects of dual targeting of tumor cells and stroma in human glioblastoma xenografts with a tyrosine kinase inhibitor against c-MET and VEGFR2.

Authors:  Anna C Navis; Annika Bourgonje; Pieter Wesseling; Alan Wright; Wiljan Hendriks; Kiek Verrijp; Jeroen A W M van der Laak; Arend Heerschap; William P J Leenders
Journal:  PLoS One       Date:  2013-03-04       Impact factor: 3.240

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.